The July 1, 2018, article by Dowsett et al entitled “Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5” (J Clin Oncol 10.1200/JCO.2017.76.4258) was published with errors.
Figure 3 has been replaced. The authors incorrectly used the baseline risk from the BIG1-98 population. The errors do not affect their interpretation of the validation in the BIG1-98 population or the final CTS5 algorithm. The corrected version uses the baseline risk from the ATAC population.
The Figure 3 legend read as: Observed versus expected number of events and χ2 values in the BIG (Breast International Group) 1-98 trial according to deciles of Clinical Treatment Score post–5 years (ATAC [Arimidex, Tamoxifen, Alone or Combination]) for (A) node-negative and (B) node-positive patients. None of the χ2 were statistically significant.
It should have read as: Observed versus expected numbers of events and χ2 values in the BIG (Breast International Group) 1-98 trial according to deciles of Clinical Treatment Score post–5 years (ATAC [Arimidex, Tamoxifen, Alone or Combination]) for (A) node-negative and (B) node-positive patients.
This has been corrected as of January 15, 2020. The authors apologize for the errors.